Concepts (99)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptors, CCR5 | 4 | 2010 | 490 | 0.950 |
Why?
|
| HIV Envelope Protein gp120 | 4 | 2010 | 925 | 0.820 |
Why?
|
| HIV-1 | 11 | 2017 | 6966 | 0.470 |
Why?
|
| Virus Attachment | 1 | 2010 | 57 | 0.340 |
Why?
|
| Conserved Sequence | 1 | 2010 | 1164 | 0.270 |
Why?
|
| Peptide Fragments | 3 | 2010 | 5152 | 0.260 |
Why?
|
| HIV Infections | 8 | 2017 | 17564 | 0.170 |
Why?
|
| Infectious Disease Transmission, Vertical | 4 | 2008 | 1359 | 0.170 |
Why?
|
| Amino Acid Substitution | 1 | 2003 | 1744 | 0.150 |
Why?
|
| Proviruses | 3 | 2006 | 320 | 0.150 |
Why?
|
| Reverse Transcriptase Inhibitors | 2 | 2011 | 622 | 0.130 |
Why?
|
| Mutagenesis, Site-Directed | 2 | 2010 | 1688 | 0.130 |
Why?
|
| Cell Fusion | 2 | 2006 | 294 | 0.120 |
Why?
|
| Cell Line | 5 | 2011 | 15609 | 0.110 |
Why?
|
| Amino Acid Sequence | 4 | 2010 | 13452 | 0.100 |
Why?
|
| Viral Load | 3 | 2017 | 3399 | 0.080 |
Why?
|
| Thymidine | 1 | 2009 | 297 | 0.080 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2010 | 435 | 0.070 |
Why?
|
| HIV Fusion Inhibitors | 1 | 2007 | 83 | 0.070 |
Why?
|
| Molecular Sequence Data | 3 | 2010 | 17647 | 0.070 |
Why?
|
| Quaternary Ammonium Compounds | 1 | 2007 | 204 | 0.070 |
Why?
|
| Disease Progression | 2 | 2017 | 13655 | 0.070 |
Why?
|
| Protein Structure, Quaternary | 1 | 2007 | 429 | 0.070 |
Why?
|
| Virus Internalization | 1 | 2010 | 501 | 0.070 |
Why?
|
| Membrane Fusion | 1 | 2007 | 265 | 0.070 |
Why?
|
| Schistosomiasis mansoni | 1 | 2006 | 94 | 0.060 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2008 | 2181 | 0.060 |
Why?
|
| Amides | 1 | 2007 | 452 | 0.060 |
Why?
|
| Infant Formula | 1 | 2006 | 195 | 0.060 |
Why?
|
| Vaccines, DNA | 1 | 2006 | 280 | 0.060 |
Why?
|
| Virus Replication | 2 | 2011 | 2459 | 0.060 |
Why?
|
| Zidovudine | 1 | 2006 | 625 | 0.060 |
Why?
|
| HIV | 1 | 2011 | 1596 | 0.060 |
Why?
|
| Protein Structure, Tertiary | 1 | 2010 | 3790 | 0.050 |
Why?
|
| Botswana | 3 | 2017 | 1059 | 0.050 |
Why?
|
| DNA, Viral | 3 | 2006 | 2206 | 0.050 |
Why?
|
| Genotype | 1 | 2017 | 13047 | 0.050 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2009 | 1064 | 0.050 |
Why?
|
| Point Mutation | 1 | 2006 | 1596 | 0.050 |
Why?
|
| Anti-HIV Agents | 2 | 2008 | 4567 | 0.050 |
Why?
|
| Virus Integration | 1 | 2003 | 306 | 0.050 |
Why?
|
| Virion | 1 | 2003 | 430 | 0.050 |
Why?
|
| Interferon-gamma | 2 | 2006 | 3169 | 0.040 |
Why?
|
| AIDS Vaccines | 1 | 2006 | 900 | 0.040 |
Why?
|
| Anti-Retroviral Agents | 1 | 2008 | 1794 | 0.040 |
Why?
|
| T-Lymphocytes | 2 | 2006 | 10273 | 0.040 |
Why?
|
| Breast Feeding | 1 | 2006 | 1365 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2007 | 6527 | 0.040 |
Why?
|
| Nevirapine | 2 | 2008 | 273 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 18048 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2010 | 6610 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2003 | 3735 | 0.030 |
Why?
|
| Protein Binding | 1 | 2006 | 9376 | 0.030 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2017 | 2596 | 0.020 |
Why?
|
| Humans | 12 | 2017 | 768451 | 0.020 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 2009 | 224 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2006 | 1855 | 0.020 |
Why?
|
| Publication Bias | 1 | 2008 | 160 | 0.020 |
Why?
|
| Mutagenesis | 1 | 2011 | 1230 | 0.020 |
Why?
|
| RNA, Viral | 2 | 2006 | 2865 | 0.020 |
Why?
|
| HIV Core Protein p24 | 1 | 2006 | 247 | 0.020 |
Why?
|
| Africa | 1 | 2008 | 726 | 0.020 |
Why?
|
| Drug Resistance, Viral | 1 | 2011 | 869 | 0.020 |
Why?
|
| Placebos | 1 | 2008 | 1668 | 0.010 |
Why?
|
| South Africa | 1 | 2008 | 1870 | 0.010 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2006 | 828 | 0.010 |
Why?
|
| Infant, Newborn | 3 | 2008 | 26395 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2011 | 6091 | 0.010 |
Why?
|
| Infant Mortality | 1 | 2006 | 756 | 0.010 |
Why?
|
| Pregnancy | 3 | 2008 | 30179 | 0.010 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2006 | 1797 | 0.010 |
Why?
|
| Cost of Illness | 1 | 2008 | 1960 | 0.010 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2006 | 1903 | 0.010 |
Why?
|
| Vagina | 1 | 2003 | 845 | 0.010 |
Why?
|
| Animals | 2 | 2006 | 169418 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2017 | 12774 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2017 | 16029 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2006 | 6241 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2006 | 6856 | 0.010 |
Why?
|
| Health Care Costs | 1 | 2008 | 3265 | 0.010 |
Why?
|
| Mutation | 2 | 2011 | 30243 | 0.010 |
Why?
|
| Infant | 2 | 2008 | 36497 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2009 | 19041 | 0.010 |
Why?
|
| Female | 5 | 2017 | 396943 | 0.010 |
Why?
|
| Rural Population | 1 | 2003 | 2317 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2017 | 54914 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2008 | 8051 | 0.010 |
Why?
|
| Adult | 3 | 2017 | 223542 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 59680 | 0.010 |
Why?
|
| Young Adult | 1 | 2017 | 60045 | 0.010 |
Why?
|
| Incidence | 1 | 2008 | 21552 | 0.010 |
Why?
|
| Time Factors | 1 | 2008 | 40271 | 0.000 |
Why?
|
| Aged | 1 | 2017 | 171520 | 0.000 |
Why?
|
| Middle Aged | 1 | 2017 | 223418 | 0.000 |
Why?
|
| Cross-Sectional Studies | 1 | 2003 | 26351 | 0.000 |
Why?
|
| Treatment Outcome | 1 | 2008 | 65409 | 0.000 |
Why?
|
| Mice | 1 | 2006 | 82045 | 0.000 |
Why?
|
| Male | 1 | 2017 | 364781 | 0.000 |
Why?
|
| Retrospective Studies | 1 | 2003 | 81834 | 0.000 |
Why?
|
Concepts
(99)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(8)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_